In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...

Biogen stock opened at $137.33 on Thursday. The company’s 50-day moving average price is $147.31 and its 200-day moving average price is $173.80. Biogen has a twelve month low of $128.51 and a ...

The only other time Biogen stock has spiked was in September 2022, when, alongside Japanese Pharma Eisai, its development partner in the Alzheimer's treatment field, the company shared data from a ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Bank Of America (Bofa) lowered their price objective on Biogen from $178.00 to $163.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, HC Wainwright ...

Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the ...

Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.